Caisse de depot et placement du Quebec Acquires New Stake in Smith & Nephew SNATS, Inc. $SNN

Caisse de depot et placement du Quebec acquired a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) during the 2nd quarter, Holdings Channel reports. The institutional investor acquired 1,023,372 shares of the medical equipment provider’s stock, valued at approximately $64,186,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Equity Investment Corp increased its stake in Smith & Nephew SNATS by 3.9% in the 4th quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock worth $246,000 after buying an additional 285 shares during the period. Smartleaf Asset Management LLC grew its stake in Smith & Nephew SNATS by 13.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,820 shares of the medical equipment provider’s stock worth $93,000 after acquiring an additional 334 shares in the last quarter. Cary Street Partners Financial LLC increased its position in shares of Smith & Nephew SNATS by 1.8% during the fourth quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock worth $665,000 after acquiring an additional 365 shares during the period. Parallel Advisors LLC increased its position in shares of Smith & Nephew SNATS by 20.0% during the first quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock worth $74,000 after acquiring an additional 387 shares during the period. Finally, Clearstead Trust LLC bought a new stake in shares of Smith & Nephew SNATS during the second quarter valued at approximately $25,000. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Wall Street Analyst Weigh In

SNN has been the subject of a number of research reports. Kepler Capital Markets lowered Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Barclays downgraded Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a report on Wednesday, August 5th. Zacks Research cut Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Wall Street Zen raised Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research report on Monday. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday, August 6th. Two investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $30.93.

Smith & Nephew SNATS Stock Down 0.6%

Shares of SNN opened at $29.14 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11. Smith & Nephew SNATS, Inc. has a 1-year low of $28.56 and a 1-year high of $38.79. The company’s fifty day moving average price is $30.24 and its 200-day moving average price is $31.70.

Smith & Nephew SNATS Dividend Announcement

The company also recently declared a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be paid a dividend of $0.312 per share. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.